logo
logo

Exai Bio Secures $67.5 Million Series A Financing To Advance Next-Generation, Rna-Based Liquid Biopsy Platform For Early Cancer Detection

Dec 09, 2021•over 3 years ago

Amount Raised

$67.5 Million

Round Type

series a

San Francisco

Description

Exai Bio, a next-generation liquid biopsy company, today announced it has raised a $67.5 million Series A financing to accelerate development of its non-invasive, RNA-based liquid biopsy platform for early cancer detection. The financing was led by leading life sciences and tech investors Section 32 and Casdin Capital, with participation from Two Sigma Ventures, who have been integral to advancing cancer diagnostics and artificial intelligence/machine learning technologies.

Company Information

Company

Exai Bio

Location

San Francisco, California, United States

About

Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech